AstraZeneca Follows Rival Boehringer in Capping Out-of-pocket Costs for Inhalers AstraZeneca Follows Rival Boehringer in Capping Out-of-pocket Costs for Inhalers

Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by...Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine Source Type: news